消化道恶性肿瘤伴癌性腹水患者腹腔化疗前后血清及腹水IL-6和sIL-6R水平变化的意义

Clinical Significance of Changes of Serum and Ascitic Fluid Levels of IL-6 and sIL-6R After Intraperitoneal Chemotherapy in Patients with G-I Tract Malignancies Complicated with Ascites

目的:探讨腹腔化疗对癌性腹水患者血清及腹水IL-6及sIL-6R水平影响及其临床意义。方法:采用放免法测定病人腹腔化疗前、治疗后四周血清及腹水IL-6水平变化,用ELISA同时测定sIL-6R水平变化,并与正常对照组相对比。结果:消化道恶性肿瘤伴癌性腹水患者血清IL-6和sIL-6R水平较正常对照组明显升高,腹水IL-6和sIL-6R水平较血清IL-6和sIL-6R水平明显增高。腹腔化疗后血清IL-6和sIL-6R水平下降,腹水IL-6和sIL-6R水平变化与血清水平变化相平行。且血清及腹水IL-6及sIL-6R水平变化与腹腔化疗是否有效有密切关系。结论:监测癌性腹水患者血清及腹水IL-6及sIL-6R水平变化是判断及预测腹腔化疗是否有效的途径之一。

Objective To study the clinical significance of changes of serum and ascitic fluid levels of IL -6 and sIL -6R after chemotherapy in patients with cancerous ascites. Methods Serum and ascitic fluid levels of IL- 6 （with RIA） and sIL -6R （with ELISA） were determined in 86 patients both before and after intraperitoneal chemotherapy as well as in 40 controls （serum levels only）. Results In patients with malignant G -I tract tumors complicated with ascites the serum IL-6 and sIL -6R levels were significantly higher than those in controls. Moreover, the ascitic fluid levels of IL -6 and sIL- 6R were significantly higher than the serum levels in there patients. After four weeks＇ intraperitoneal chemotherapy, the serum IL- 6 and sIL- 6R levels dropped markedly in patients with satisfactory response, with the ascitic fluid levels decreased simultaneously. The levels changed little in patients refractory to intraperitmeal chemotherapy. Conclusion Serum and ascitic fluid levels of IL -6 and sIL -6R could be prognostic factor for intraperitoneal chemotherapy.